Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines

Khan, Tila; Heffron, C. Lynn; High, Kevin P.; Roberts, Paul C.

Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines

dc.contributor.author	Khan, Tila	en
dc.contributor.author	Heffron, C. Lynn	en
dc.contributor.author	High, Kevin P.	en
dc.contributor.author	Roberts, Paul C.	en
dc.date.accessioned	2014-05-28T11:31:59Z	en
dc.date.available	2014-05-28T11:31:59Z	en
dc.date.issued	2014-05-03	en
dc.date.updated	2014-05-28T11:32:00Z	en
dc.description.abstract	Background Potent and safe adjuvants are needed to improve the efficacy of parenteral and mucosal vaccines. Cytokines, chemokines and growth factors have all proven to be effective immunomodulatory adjuvants when administered with a variety of antigens. We have previously evaluated the efficacy of membrane-anchored interleukins (IL) such as IL-2 and IL-4 co-presented as Cytokine-bearing Influenza Vaccines (CYT-IVACs) using a mouse model of influenza challenge. Findings Here, we describe studies evaluating the parenteral and mucosal adjuvanticity of membrane-bound IL-12 and IL-23 CYT-IVACs in young adult mice. Mucosal immunization using IL-12 and IL-23 bearing whole influenza virus vaccine (WIV) was more effective at eliciting virus-specific nasal IgA and reducing viral lung burden following challenge compared to control WIV vaccinated animals. Both IL-12 and IL-23 bearing WIV elicited the highest anti-viral IgA levels in serum and nasal washes. Conclusions This study highlights for the first time the mucosal adjuvant potential of IL-12 and IL-23 CYT-IVAC formulations in eliciting mucosal immune responses and reducing viral lung burden. The co-presentation of immunomodulators in direct context with viral antigen in whole inactivated viral vaccines may provide a means to significantly lower the dose of vaccine required for protection.	en
dc.description.version	Published version	en
dc.format.mimetype	application/pdf	en
dc.identifier.citation	Virology Journal. 2014 May 03;11(1):78	en
dc.identifier.doi	https://doi.org/10.1186/1743-422X-11-78	en
dc.identifier.uri	http://hdl.handle.net/10919/48127	en
dc.language.iso	en	en
dc.rights	Creative Commons Attribution 4.0 International	en
dc.rights.holder	Tila Khan et al.; licensee BioMed Central Ltd.	en
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	en
dc.title	Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines	en
dc.title.serial	Virology Journal	en
dc.type	Article - Refereed	en
dc.type.dcmitype	Text	en